Exicure to Reveal Latest Burixafor Phase 2 Trial Data
Exicure’s open-label, multicenter Phase 2 trial in multiple myeloma reported that 89.7% of patients met the study’s primary mobilization...
Comphya CaverSTIM Study Published in BJUI, Nature Urology
In a first-in-human pilot of 10 preoperatively potent men undergoing nerve‑sparing robotic radical prostatectomy, Comphya’s implantable cavernous nerve neurostimulator...
Nxera Pharma Reports Successful Daridorexant Phase 3 Trial
Daridorexant 50 mg met the primary endpoint of change from baseline in subjective total sleep time at Day 28...
New Study IDs Way to Prevent and Treat Lyme Arthritis
In preclinical Lyme disease models, subtle alterations to the Borrelia burgdorferi peptidoglycan nearly eliminated arthritis despite ongoing infection at...
BioAge Announces Promising New Trial for Macular Edema Drug
In preclinical models of diabetic macular edema, oral BGE-102 nearly eliminated retinal vascular leakage and preserved up to 90%...
Tiziana Life Sciences Publishes Intranasal Foralumab Study
In an open-label study of 10 patients with non-active secondary progressive multiple sclerosis, intranasal foralumab showed no serious or...
Clinical Trial Tests D-Serine to Modify Parkinson’s Disease
SPARK NS and Haukeland University Hospital will run a randomized, double-blind, placebo-controlled Phase 2b trial of oral D-serine in...
Orphai’s LAM-001 Study Selected for ATS 2026 Presentation
No efficacy or safety data were released, but Orphai Therapeutics will present 24-week Phase 2a results of inhaled sirolimus...
Spyglass Pharma Begins Phase III Trials for BIM-IOL System
SpyGlass Pharma has randomized the first patients into two registrational Phase III trials, SGP-005 and SGP-006, evaluating its Bimatoprost...
Rein’s Breakthrough IPF Drug Gets Rare EU Orphan Status
Rein Therapeutics secured European orphan drug designation for LTI-03 in idiopathic pulmonary fibrosis, adding regulatory leverage to a program...